MedPath

Antibiotic Use in a Neonatal Intensive Care Unit Practicing Integrative Medicine

Completed
Conditions
Neonatal Infection
Interventions
Other: No antibiotic treatment
Other: Antibiotic treatment
Registration Number
NCT04893343
Lead Sponsor
ARCIM Institute Academic Research in Complementary and Integrative Medicine
Brief Summary

The goal of this study is to describe the antibiotic use in a neonatal intensive care unit (NICU) in Germany that is practising integrative medicine. The investigators will review hospital records to find out how often and how long antibiotics were given to newborns; compare antibiotic use to other NICU in the same area; describe how sick infected newborns were (comparing those treated with or without antibiotics); and describe which anthroposophic medicines were used, how often and if there were safety problems.

Detailed Description

A retrospective study, analysing antibiotic use in a level 2 neonatology intensive care unit (NICU) in Germany over a 4-year period from 2014 to 2017. The study will analyse frequency of antibiotic prescribing; compare antibiotic use to other level 2 NICU; compare clinical and laboratory parameters among neonates with infectious disease diagnosis managed with or without antibiotics; use and tolerability of anthroposophic medicinal products.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
246
Inclusion Criteria
  • Admission to neonatal intensive care unit
Exclusion Criteria
  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Neonatal infection without antibioticsNo antibiotic treatmentIn-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
Neonatal infection with antibioticsAntibiotic treatmentIn-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
Primary Outcome Measures
NameTimeMethod
Antibiotic prescription rateJanuary 1, 2014 to December 31, 2017

Number of antibiotic treatment days per 100 hospital days

Secondary Outcome Measures
NameTimeMethod
Antibiotic treatment durationJanuary 1, 2014 to December 31, 2017

Mean treatment duration and distribution among recommended therapy durations: 48 hours, 5 days and 7-10 days durations

Clinical and laboratory parameters in neonates with infectious disease diagnosis: Mother group B streptococcus positiveJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: Mother tested positive for group B streptococcus

Clinical and laboratory parameters in neonates with infectious disease diagnosis: Low birthweightJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: Neonates with low birthweight (\< 2500 g)

Clinical and laboratory parameters in neonates with infectious disease diagnosis: Infant fever on admissionJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: Infant fever on admission (≥ 38.0° C)

Clinical and laboratory parameters in neonates with infectious disease diagnosis: CRP maximum valueJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: Maximum value of C-reactive protein (mg/l)

Clinical and laboratory parameters in neonates with infectious disease diagnosis: Premature rupture of membranesJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: Premature rupture of membranes \>24h before birth

Clinical and laboratory parameters in neonates with infectious disease diagnosis: Leukocyte count maximum valueJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: Maximum value of leukocyte count (cells per liter)

Use of anthroposophic medications: frequency of useJanuary 1, 2014 to December 31, 2017

Anthroposophic medications: frequency of use per medication

Safety of anthroposophic medications: adverse drug reactionsJanuary 1, 2014 to December 31, 2017

Recording of anthroposophic medication adverse drug reactions (ADR, in grades I-IV, ADR as % of prescriptions)

Antibiotic use compared to other level 2 NICU in same geographic areaJanuary 1, 2014 to December 31, 2017

Proportion of neonates having received any antibiotic, compared to proportion in other level 2 NICU in the same geographic area

Clinical and laboratory parameters in neonates with infectious disease diagnosis: pH umbilical artery at birthJanuary 1, 2014 to December 31, 2017

Descriptive analysis of clinical and laboratory parameters in neonates with ICD-10 infectious disease diagnosis, treated with and without antibiotics. Here: pH of umbilical artery blood at birth

Antibiotic typeJanuary 1, 2014 to December 31, 2017

Types of antibiotics used, frequency of use per antibiotic type

Use of anthroposophic medications: medication namesJanuary 1, 2014 to December 31, 2017

Anthroposophic medications: names of the medications used

Safety of anthroposophic medications: side effectsJanuary 1, 2014 to December 31, 2017

Recording of anthroposophic medication side effects

Trial Locations

Locations (1)

Die Filderklinik

🇩🇪

Filderstadt, Baden-Württemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath